FOSAPREPITANT DIMEGLUMINE Drug Patent Profile
✉ Email this page to a colleague
When do Fosaprepitant Dimeglumine patents expire, and when can generic versions of Fosaprepitant Dimeglumine launch?
Fosaprepitant Dimeglumine is a drug marketed by Accord Hlthcare, Apotex, Arthur Grp, Aspiro, Baxter Hlthcare Corp, Be Pharms, Chia Tai Tianqing, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Lupin Ltd, MSN, Mylan Labs Ltd, Navinta Llc, Piramal Critical, Qilu Pharm Hainan, Sandoz, and Teva Pharms Usa. and is included in nineteen NDAs.
The generic ingredient in FOSAPREPITANT DIMEGLUMINE is fosaprepitant dimeglumine. There are eleven drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the fosaprepitant dimeglumine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fosaprepitant Dimeglumine
A generic version of FOSAPREPITANT DIMEGLUMINE was approved as fosaprepitant dimeglumine by FRESENIUS KABI USA on June 9th, 2016.
Summary for FOSAPREPITANT DIMEGLUMINE
Recent Clinical Trials for FOSAPREPITANT DIMEGLUMINE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 3 |
Xijing Hospital | N/A |
University of Lahore | Phase 3 |
Pharmacology for FOSAPREPITANT DIMEGLUMINE
Anatomical Therapeutic Chemical (ATC) Classes for FOSAPREPITANT DIMEGLUMINE
Paragraph IV (Patent) Challenges for FOSAPREPITANT DIMEGLUMINE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
EMEND | Injection | fosaprepitant dimeglumine | 150 mg/vial | 022023 | 2 | 2012-01-25 |